Aerosmith Cancel Tour Indefinitely, Cite 'Serious Injury'

By Logan DeLoye

September 29, 2023

Aerosmith "Farewell Tour" Opener - Philadelpha, PA
Photo: Lisa Lake / Getty Images Entertainment / Getty Images

Aerosmith just announced that all tour dates for the rest of the year are officially canceled as a result of lead singer Steven Tyler's serious vocal chord injury. The band took to Instagram to detail the severity of the injury to fans, stating that Tyler is currently receiving exceptional medical care and needs to give his vocal cords time to heal.

"Unfortunately, Steven’s vocal injury is more serious than initially thought. His doctor has confirmed that in addition to the damage to his vocal cords, he fractured his larynx which requires ongoing care. He is receiving the best medical treatment available to ensure his recovery is swift, but given the nature of a fracture, he is being told patience is essential."

The post also mentioned that all Aerosmith shows for the rest of the year will be postponed to 2024 with updates to be announced at a later date. This news arrives just a few weeks after Tyler announced that he would not be singing for at least 30 days under strict "doctor's orders" as a result of the vocal cord injury. The artist personally shared a message with fans and followers to let them know that the band would be back in action "as soon as we can."

“I am heartbroken to not be out there with Aerosmith, my brothers, and the incredible Black Crowes, rocking with the best fans in the world. I promise we will be back as soon as we can!”

Those who already purchased tickets for a 2023 PEACE OUT show will be granted access to a respective rescheduled date in 2024. Ticketholders that cannot make the new date will be refunded. Tyler continues to allow time for his vocal cords to heal as fans patiently await news of a good bill of health from the rock icon.

AerosmithSteven Tyler
Advertise With Us
Music, radio and podcasts, all free. Listen online or download the iHeart App.

Connect

© 2024 iHeartMedia, Inc.